Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile

INTRODUCTION: Severe acute respiratory syndrome virus 2 (SARS-CoV-2) has caused over million deaths worldwide, with more than 61,000 deaths in Chile. The Chilean government has implemented a vaccination program against SARS-CoV-2, with over 17.7 million people receiving a complete vaccination scheme...

Descripción completa

Detalles Bibliográficos
Autores principales: Díaz-Dinamarca, Diego A., Díaz, Pablo, Barra, Gisselle, Puentes, Rodrigo, Arata, Loredana, Grossolli, Jonnathan, Riveros-Rodriguez, Boris, Ardiles, Luis, Santelises, Julio, Vasquez-Saez, Valeria, Escobar, Daniel F., Soto, Daniel, Canales, Cecilia, Díaz, Janepsy, Lamperti, Liliana, Castillo, Daniela, Urra, Mychel, Zuñiga, Felipe, Ormazabal, Valeska, Nova-Lamperti, Estefanía, Benítez, Rosana, Rivera, Alejandra, Cortes, Claudia P., Valenzuela, María Teresa, García-Escorza, Heriberto E., Vasquez, Abel E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483147/
https://www.ncbi.nlm.nih.gov/pubmed/37693706
http://dx.doi.org/10.3389/fpubh.2023.1229045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483147/
https://www.ncbi.nlm.nih.gov/pubmed/37693706
http://dx.doi.org/10.3389/fpubh.2023.1229045

Ejemplares similares